Skip to content
MS
Sign in
rate-limiting unreviewed

IMP dehydrogenase (IMPDH)

1 reactions · 1 pathways

Cofactors used

H2O NAD+ · B3 (Niacin) NADH · B3 (Niacin)

What it does, reaction by reaction

1 reactions

Purine De Novo Synthesis (IMP synthesis through to AMP/GMP) Nucleotide Metabolism · Cytosol

step 14 Irreversible/directional

IMP → xanthosine monophosphate (XMP)

Converts IMP into Xanthosine monophosphate (XMP)

› Notes

IMP dehydrogenase (IMPDH) catalyzes IMP + NAD+ + H2O → XMP + NADH + H+. This oxidation establishes the 2-keto group needed for subsequent amination and is the committed, regulatory step of the GMP branch.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Purine De Novo Synthesis (IMP synthesis through to AMP/GMP)

Listed there as: IMP dehydrogenase

Accelerated by

IMP; increased AMP demand can favor GMP synthesis through reciprocal branch control

Inhibited by

GMP and GDP

Hormonal control

Increased expression accompanies lymphocyte activation and cell proliferation; no major direct endocrine allosteric control.

Recent literature

Refresh

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Gut metaproteomics reveals activated arginine catabolism and impaired arginine biosynthesis in systemic lupus erythematosus.

    Xiong W, Zheng X, Yuan L, Yin L, Tang D, Dai Y, Wang Q. · 2026-07-10

    unreviewed
  2. 2
    Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data.

    Mouton M, Davidson B, Taylor J, Blockman M, Jones E, Freercks R, Mnika K, Dandara C. · 2026-05-01

    open access unreviewed
  3. 3
    Integrated transcriptomic and metabolomic analyses reveal targeting hexokinase 2 disrupts glycolysis and nucleotide metabolism to inhibit NSCLC growth.

    Zhou J, Deng R, Pan L, Zhao Q, Wang Y, Wang Q, Liu Y, Yu Y. · 2026-05-14

    open access unreviewed
  4. 4
    IMP metabolic mechanisms and IMPDH targeting strategies in tumor metabolic reprogramming and therapy (Review).

    Zhu H, Wang H, Li X, Zhang W, Wang Y, Tan Q, Ying D, Shi Z, Song J. · 2026-02-06

    open access unreviewed
  5. 5
    Chronological lifespan extension and nucleotide salvage inhibition in yeast by isonicotinamide supplementation.

    Kalita AI, Letai CT, Enriquez-Hesles E, Power LN, Mishra S, Saha S, Dinda M, Wang D, Singh PK, Smith JS. · 2026-01-13

    open access unreviewed
  6. 6
    Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.

    Kawano G, Ikeda R, Ishihara D, Shima T, Sakoda T, Yamamoto S, Kochi Y, Semba Y, Ashitani S, Mori Y, Kato K, M… · 2026-02-01

    cited 1× open access unreviewed
  7. 7
    Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications.

    Wang X, Luo X, Xiao R, Liu X, Zhou F, Jiang D, Bai J, Cui M, You L, Zhao Y. · 2026-01-26

    cited 9× open access unreviewed
  8. 8
    ppAT drives glutamine-dependent purine biosynthesis and malignant progression in hepatocellular carcinoma.

    Zhou J, Dong C, Xu S, Wang J, Ye H, Fan X, Li S, Wang S. · 2026-01-21

    open access unreviewed
  9. 9
    Digital twins for in vivo metabolic flux estimations in patients with brain cancer.

    Meghdadi B, Al-Holou WN, Scott AJ, Mittal A, Liang N, Sravya P, Achreja A, O'Brien A, Do K, Wu Z, Feng J, Qi … · 2025-12-01

    cited 1× unreviewed
  10. 10
    Challenges and opportunities for oncology drug repurposing informed by synthetic lethality.

    Vermeulen M, Craig AW, Babak T. · 2025-12-13

    cited 1× open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.